Matias Carolina do Nascimento, Lima Vladmir, Teixeira Heberton Medeiros, Souto Fernanda Ribeiro, Magalhães Vera
Universidade Federal de Pernambuco - UFPE, Recife, PE, Brazil.
Rev Bras Hematol Hemoter. 2013;35(1):39-43. doi: 10.5581/1516-8484.20130013.
To determine the prevalence of hyperglycemia during induction therapy in adult patients with acute leukemia and its effect on complicated infections and mortality during the first 30 days of treatment.
An analysis was performed in a retrospective cohort of 280 adult patients aged 18 to 60 years with previously untreated acute leukemia who received induction chemotherapy from January 2000 to December 2009 at the Hemocentro de Pernambuco (HEMOPE), Brazil. Hyperglycemia was defined as the finding of at least one fasting glucose measurement > 100 mg/dL observed one week prior to induction therapy until 30 days after. The association between hyperglycemia and complicated infections, mortality and complete remission was evaluated using the Chi-square or Fisher's exact tests by the Statistical Package for Social Sciences (SPSS) in the R software package version 2.9.0.
One hundred and eighty-eight patients (67.1%) presented hyperglycemia at some moment during induction therapy. Eighty-two patients (29.3%) developed complicated infections. Infection-related mortality during the neutropenia period was 20.7% (58 patients). Mortality from other causes during the first 30 days after induction was 2.8%. Hyperglycemia increased the risk of complicated infections (OR 3.97; 95% confidence interval: 2.08 - 7.57; p-value < 0.001) and death (OR 3.55; 95% confidence interval: 1.77-7.12; p-value < 0.001) but did not increase the risk of fungal infections or decrease the probability of achieving complete remission.
This study demonstrates an association between the presence of hyperglycemia and the development of complicated infections and death in adult patients during induction therapy for acute leukemia.
确定成年急性白血病患者诱导治疗期间高血糖的发生率及其对治疗前30天内并发感染和死亡率的影响。
对2000年1月至2009年12月在巴西伯南布哥血液中心(HEMOPE)接受诱导化疗的280例年龄在18至60岁、既往未接受过治疗的成年急性白血病患者进行回顾性队列分析。高血糖定义为诱导治疗前一周至治疗后30天内至少一次空腹血糖测量值>100mg/dL。使用社会科学统计软件包(SPSS)在R软件包2.9.0版中通过卡方检验或Fisher精确检验评估高血糖与并发感染、死亡率和完全缓解之间的关联。
188例患者(67.1%)在诱导治疗期间的某个时刻出现高血糖。82例患者(29.3%)发生了复杂感染。中性粒细胞减少期与感染相关的死亡率为20.7%(58例患者)。诱导后前30天内其他原因导致的死亡率为2.8%。高血糖增加了并发感染的风险(比值比3.97;95%置信区间:2.08 - 7.57;p值<0.001)和死亡风险(比值比3.55;95%置信区间:1.77 - 7.12;p值<0.001),但未增加真菌感染的风险或降低实现完全缓解的概率。
本研究表明成年急性白血病患者诱导治疗期间高血糖的存在与并发感染及死亡之间存在关联。